Study study type PathologyT1T0Patientssample sizesROB Results

la/mBC - HR positive - L2 - PIK3CA mutant breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2) la/mBC - HR positive - L2 - PIK3CA mutant

versus fulvestrant
buparlisib plus fulvestrant
BELLE-2 (PI3K pathway activated), 2017
  NCT01610284
RCTla/mBC - HR positive - L2 - PIK3CA mutantbuparlisib plus fulvestrantplacebo plus fulvestrantPostmenopausal women (>=18yr), with histollogically confirmed HR-positive and HER2-negative inoperable locally advanced or metastatic breast cancer (with progession on or after aromatase ihnibitor treatment). This subgroup population included only patients with PI3K pathway activated188 / 184low
suggested
  • suggested 24 % decrease in progression or deaths (PFS) (PE)